"The voice for cancer physicians and their patients in Massachusetts."

FDA Approves Ramucirumab fro hepatocellular carcinoma (HCC)

13 May 2019 7:36 AM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration approved ramucirumab (Cyramza; Lilly) as a single agent for hepatocellular carcinoma (HCC) in patients who have an alpha fetoprotein (AFP of  ≥ 400 ng/mL and have been previously treated with sorafenib. Read full press release.

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software